Stockscreener 앱 받기
2.64
0.76%
0.02
시간 외 거래:
2.62
-0.02
-0.76%
Clene Inc 주식(CLNN)의 최신 뉴스
Clene inc. sees $1,089 stock sale by major shareholder - Investing.com South Africa
Clene Approves Stock Plan Amendment at Annual Meeting - TipRanks
Clene stock touches 52-week low at $2.5 amid market challenges By Investing.com - Investing.com South Africa
Clene stock touches 52-week low at $2.5 amid market challenges - Investing.com Australia
Brokerages Set Clene Inc. (NASDAQ:CLNN) Target Price at $40.00 - Defense World
Clene eyeing regulatory submission for CNM-Au8 in ALS by year’s end - ALS News Today
Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates - MSN
HC Wainwright Issues Positive Forecast for Clene Earnings - Defense World
Roth Capital Has Optimistic Outlook of Clene Q2 Earnings - Defense World
Benchmark Lowers Clene (NASDAQ:CLNN) Price Target to $33.00 - Defense World
D. Boral Capital Reaffirms Buy Rating for Clene (NASDAQ:CLNN) - Defense World
Clene Inc. Reports Reduced Losses Amid Strategic Cost-Saving Measures - TipRanks
Promising Nanotechnology Stocks To Watch Now – May 7th - The AM Reporter
Clene Inc. Advances CNM-Au8 Treatment for ALS, Reports Promising Q1 Results - citybuzz -
Clene Inc. Advances CNM-Au8 Toward Potential Accelerated Approval for ALS - citybuzz -
Clene’s Strategic Financial Management and Promising Clinical Developments Drive Buy Rating - TipRanks
Clene (CLNN) Maintains Buy Rating Despite Price Target Reduction - GuruFocus
Clene (CLNN) Stock Rating and Price Target Maintained at Buy | CLNN Stock News - GuruFocus
Renaissance Technologies LLC Invests $96,000 in Clene Inc. (NASDAQ:CLNN) - Defense World
Clene Inc. to Showcase Neurodegenerative Research at D. Boral Capital Global Conference - citybuzz -
Clene (CLNN) Reports Decline in Cash Reserves | CLNN Stock News - GuruFocus
Clene Faces Nasdaq Delisting Risk Amid Regulatory Pursuits - TipRanks
Clene (CLNN) Exceeds Revenue Expectations and Advances ALS Research | CLNN Stock News - GuruFocus
Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights - The Manila Times
Clene Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference | CLNN Stock News - GuruFocus
Clene Inc. SEC 10-Q Report - TradingView
Clene Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference - The Kingston Whig Standard
Geode Capital Management LLC Grows Stake in Clene Inc. (NASDAQ:CLNN) - Defense World
Clene Inc. expected to post a loss of 95 cents a shareEarnings Preview - TradingView
Clene Inc. Enters Agreement for $25M Equity Distribution By Investing.com - Investing.com Nigeria
Clene Inc. Enters Agreement for $25M Equity Distribution - Investing.com Australia
Clene Inc.Enters Equity Distribution Agreement With CanaccordSEC Filing - marketscreener.com
Analysts Set Clene Inc. (NASDAQ:CLNN) Target Price at $55.25 - Defense World
Clene (NASDAQ:CLNN) Research Coverage Started at Jones Trading - Defense World
Clene (CLNN) Receives Buy Rating and $30 Target from JonesResear - GuruFocus
Clene (CLNN) Receives Buy Rating and $30 Target from JonesResearch | CLNN Stock News - GuruFocus
Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream - GlobeNewswire
Clene to Present at the Emerging Growth Conference | CLNN Stock News - GuruFocus
Nanomedicines Market to Witness Massive Growth by 2032 | Abbott - openPR.com
Clene to Present at the Emerging Growth Conference - The Manila Times
Clene’s (CLNN) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Nanomedicines Market Generated Opportunities, Future Scope 2025-2032 | Abbott, CombiMatrix, Clene Nanomedicine - newstrail.com
Clene’s (CLNN) Buy Rating Reiterated at HC Wainwright - Defense World
Clene reports MS patient improvements with CNM-Au8 treatment By Investing.com - Investing.com India
Clene announces evidence of remyelination, neuronal repair with CNM-Au8 - TipRanks
Clene reports MS patient improvements with CNM-Au8 treatment - Investing.com Australia
0.17%
0.27%
자본화:
|
볼륨(24시간):